Unlock this StockReport nowClick to Unlock

Yourgene Health Share Price

YGEN 11p 0.0  0.0%
16/08/19 30.0k

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Mar 2013 2014 2015 2016 2017 2018 TTM 2019E 2020E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p

FINANCIAL BRIEF: For the six months ended 30 September 2018, Yourgene Health PLC revenues increased 45% to £3.9M. Net loss decreased 30% to £3.4M. Revenues reflect International segment increase of 53% to £2.6M, Europe segment increase of 41% to £716K. Lower net loss reflects Litigation expenses decrease from £1.3M (expense) to £0K, General administrative expenses decrease of 4% to £4.4M (expense). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 30th Sep '18) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Mar 2019
31st Mar 2020

Price Target: 0.20
(+81.81% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
2 brokers Broker Consensus Trend
Broker Recommendations for Yourgene Health
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 0 1

Named Brokers and Analysts
Stifel Nicolaus and Company, Incorporated Christian Glennie , Panmure Gordon Mike Mitchell , Hardman & Company Martin Hall , FinnCap ,

Profile Summary

Yourgene Health PLC, formerly Premaitha Health PLC, is engaged in molecular diagnostics business for research into, and the development and commercialization of gene analysis techniques for pre-natal screening and other clinical applications in the early detection, monitoring and treatment of disease. The Company's product, the IONA test is a non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer a regulated non-invasive prenatal test in-house. The IONA test estimates the risk of a fetus having Down's syndrome or other serious genetic diseases. The risks that fetus may be affected with include Trisomy 21 (Down's syndrome), Trisomy 18 (Edwards' syndrome), Trisomy 13 (Patau's syndrome) and Fetal sex determination optional. The analysis is performed on cell-free placental deoxyribonucleic acid (DNA) from a maternal blood sample, with test results available in three days turnaround time.

Directors: Lyn Rees (CEO) 45, Stephen Little (VCH) , Barry Hextall (CFO) 47, Keng Hsu (COO) 40, William Denman (EDR) 52, Hayden Jeffreys (OTH) 42, Adam Reynolds (NEC) 55, Bill Chang (DRC) , Nicholas Mustoe (NED) 52, John Brown (NID) 64,

No. of Employees: 91 No. of Shareholders: n/a

Last Annual March 31st, 2018
Last Interim September 30th, 2018
Incorporated April 13, 2000
Public Since May 21, 2002
Shares in Issue 598,999,688
Free Float 360.0m (60.1%)
Sector Technology
Industry Software & IT Services
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

YGEN Share Price Performance YGEN Share Price Quote
0.0  0.0%
Traded 4:10pm · Minimum 15 min delayed · NMS: 30.0k

Latest YGEN News Announcements (delayed)

Upcoming YGEN Events
Thursday 26th September, 2019 (estimate)
Full Year 2019 Yourgene Health PLC Earnings Release

Recent ↓
Monday 3rd December, 2018
Half Year 2019 Yourgene Health PLC Earnings Release
Friday 28th September, 2018
Full Year 2018 Premaitha Health PLC Earnings Release
Friday 29th December, 2017
Half Year 2018 Premaitha Health PLC Earnings Release

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.

Should you buy YGEN

Access YGEN Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis